IP Library Granted Patent US 8,343,507
Granted Patent B2
US 8,343,507 · App. 13/493,909 · Granted Jan 1, 2013

Protein from

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,343,507
App. No.
13/493,909
Granted
Jan 1, 2013
Kind
B2
Abstract

A derivative of a 55 kDa extracellular protein from Photobacterium damselae subsp. piscicida is the basis for a vaccine against Photobacterium infection, and thereby protects fish from pasteurellosis.

Claims (31)

1. A method of preparing a vaccine against pasteurellosis, comprising:

(a) growing Photobacterium damselae subsp. piscicida cells to mid-exponential phase in culture;

(b) separating supernatant from the cells, where a 55 kDa apoptogenic protein is the major protein present in the supernatant; and

(c) inactivating the supernatant with an inactivating agent.

2. The method of claim 1 , where the culture contains iron at a concentration of less than 15 μM.

3. The method of claim 1 , where the culture contains iron at a concentration of less than 10 μM.

4. The method of claim 1 , where the culture contains iron at a concentration of less than 1 μM.

5. The method of claim 1 , where the culture contains iron at a concentration of less than 0.1 μM.

6. The method of claim 1 , comprising concentrating the supernatant prior to inactivating the supernatant.

7. The method of claim 1 , comprising incorporating the supernatant that has been inactivated into a vaccine.

8. A method of preparing a vaccine against pasteurellosis, comprising:

(a) growing Photobacterium damselae subsp. piscicida cells to mid-exponential phase in culture;

(b) separating supernatant from the cells, where a 55 kDa apoptogenic protein is the major protein present in the supernatant;

(c) concentrating the supernatant;

(d) inactivating the supernatant; and

(e) incorporating the supernatant into a vaccine.

9. The method of claim 8 , where the culture contains iron at a concentration of less than 15 μM.

10. The method of claim 8 , where the culture contains iron at a concentration of less than 10 μM.

11. The method of claim 8 , where the culture contains iron at a concentration of less than 1 μM.

12. The method of claim 8 , where the culture contains iron at a concentration of less than 0.1 μM.

13. A method of preparing a vaccine against pasteurellosis, comprising:

(a) growing Photobacterium damselae subsp. piscicida cells to mid-exponential phase in a culture that is not supplemented with iron;

(b) separating supernatant from the cells;

(c) purifying a 55 KDa apoptogenic protein from the supernatant;

(d) inactivating the protein; and

(e) incorporating the protein into a vaccine.

14. The method of claim 13 , where the 55 kDa apoptogenic protein is the major protein present in the supernatant.

15. The method of claim 13 , where the culture contains iron at a concentration of less than 15 μM.

16. The method of claim 13 , where the culture contains iron at a concentration of less than 10 μM.

17. The method of claim 13 , where the culture contains iron at a concentration of less than 1 μM.

18. The method of claim 13 , where the culture contains iron at a concentration of less than 0.1 μM.

Assignments (3)
CHANGE OF NAME Recorded Aug 25, 2017
From: NOVARTIS TIERGESUNDHEIT AG
To: ELANCO TIERGESUNDHEIT AG
Reel/Frame 043402/0486 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 10, 2015
From: NOVARTIS AG
To: NOVARTIS TIERGESUNDHEIT AG
Reel/Frame 034926/0543 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 16, 2012
From: DOS SANTOS, NUNO MIGUEL SIMOES; DO VALE, ANA MARIA SILVA; TEIXEIRA DA SILVA, MANUEL ALEXANDRE; DA SILVA AZEVEDO, JORGE EDUARDO
To: NOVATIS AG
Reel/Frame 029312/0063 →